Cargando…
GVHD Prophylaxis 2020
Graft-vs. host disease (GVHD), both acute and chronic are among the chief non-relapse complications of allogeneic transplantation which still cause substantial morbidity and mortality despite significant advances in supportive care over the last few decades. The prevention of GVHD therefore remains...
Autores principales: | Gooptu, Mahasweta, Antin, Joseph Harry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059368/ https://www.ncbi.nlm.nih.gov/pubmed/33897681 http://dx.doi.org/10.3389/fimmu.2021.605726 |
Ejemplares similares
-
Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023) -
Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells
por: Maurer, Katie, et al.
Publicado: (2023) -
Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies
por: Naserian, Sina, et al.
Publicado: (2020) -
Antigen-Specific Priming is Dispensable in Depletion of Apoptosis-Sensitive T Cells for GvHD Prophylaxis
por: Yarkoni, Shai, et al.
Publicado: (2014) -
Regulatory T Cells in GVHD Therapy
por: Guo, Wen-wen, et al.
Publicado: (2021)